A phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and dose expansion study of the peptide drug conjugate (PDC), TS-104, as a monotherapy in subjects with advanced solid tumors
Not yet recruiting
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
The main goals of this study are to:
* Find the recommended dose of TS-104 that can…
Phase 1 • Sponsor: TwoStep Therapeutics, Inc.
Last updated Sep 10, 2026 15:00 UTC